The societal value of pharmaceuticals balancing industrial and healthcare policy

PharmacoEconomics

Volumn 10, Issue 1, 1996, Pages 14-22

  Grund, Jan ^a  

^a BI NORWEGIAN BUSINESS SCHOOL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; HEALTH CARE POLICY; PRIORITY JOURNAL; REVIEW;

EID: 0029987215     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199610010-00003     Document Type: Review

References (27)

1. James BG. The pharmaceutical industry in 2000: reinvesting the pharmaceutical company. London: The Economist Intelligence Unit, 1994
2. Abrahams P. Bitter medicines for producers [letter]. Financial Times 1994 Sep 30: 2
3. Rettig RA. Medical innovation duels cost containment. Health Aff 1994 Summer: 7-28
4. Easton DA. System analysis of political life. Chicago: University Express, 1965
5. Øvretveit J. Purchasing for health. Philadelphia: Open University Press, 1995
6. Stigler G. The theory of economic regulation. Bell J Econ Manag Sci 1971; 2 (1): 3-21
7. Drummond MF, Rutten F, Brenna A, et al. Economic evaluation of pharmaceuticals: a European perspective. PharmacoEconomics 1993; 3: 173-86
8. Sosialdepartementet. Helsepolitikken mot år 2000: nasjonal helseplan. Stortingsmelding nr. 41 (1987-88). Oslo: Sosialdepartementet, 1988
9. Chain EB. Academic and industrial contributions to drug research. Nature 1963 Nov: 200-441
10. Siskind DA. Contributions of the pharmaceutical industry to improved health. In: Lindsay CM, editor. The pharmaceutical industry. New York: John Wiley & Sons, 1978
11. Hoffmeyer UK, McCarthy TR. Financing health care. Dordrecht: Kluwer Academic Publishers, 1994
12. Organisation for Economic Cooperation and Development (OECD). The reform of health care: a comparative analysis of seven countries. Paris: OECD, 1992
13. Abel-Smith B. Health reform: old wine in new bottles. Eurohealth 1995; 1 (1): 7-9
14. Maynard A. Whither OTC medicines? Swiss Pharma 1994; 5-S: 15-7
15. Anderson GM, Spitzer WO, Weinstein MC, et al. Benefits, risks and costs of prescription drugs: a scientific basis for evaluating policy options. Clin Pharmacol Ther 1990; 48: 111-9
16. Grund J, Husbyn H. The role of pharmacoeconomics in health policy and management in Norway. PharmacoEconomics 1995; 7 (6): 475-83
17. Jönsson B. Economic evaluation of medicines: why and how? Nordiska Lakemedelsnamden 1995; 38: 11-9
18. Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee. Canberra: Government Publishing Service, 1995
19. Porter ME. Competitive strategy. New York: Free Press, 1980
20. Commission of the European Communities. On the outlines of an industrial policy for the pharmaceutical sector in the European Community. COM (93) 718 final. Brussels: 02.03, 1994
21. Gelijns A, Rosenberg N. The dynamics of technological change in medicine. Health Aff 1994 Sum: 28-46
22. Hafslund Nycomed. Årsmelding 1994 [annual report]. Oslo: Hafslund Nycomed, 1995
23. Amdam RP, Sogner K. Rik på kontraster. Oslo: Ad Notam Gyldendal, 1994
24. Sogner K. Nations, clusters and culture: Nycomed and world leadership in the field of X-ray contrast media. Scand Econ Hist Rev 1993; 3: 209-20
25. Maynard A. The regulation of the pharmaceutical industry. In: Drummond MF, Maynard A, editors. Purchasing and providing cost-effective health care. London: Churchill Livingstone, 1993
26. Bloom D. In need of care [letter]. Economist 1995 Aug 12; 7927: 4-5
27. Atkinson SH. University-affiliated venture capital funds. Health Aff 1994 Summer: 159-76